Circulating HPV DNA as a Biomarker for Pre-Invasive and Early Invasive Cervical Cancer: A Feasibility Study
Authors:
- Stacey J. BryanSBStacey J. Bryan
- Jen LeeJLJen Lee
- Richard GunuRGRichard Gunu
- Allison JonesAJAllison Jones
- Adeola OlaitanAOAdeola Olaitan
- Adam N. RosenthalARAdam N. Rosenthal
- Ros J. CuttsRCRos J. Cutts
- Isaac Garcia-MurillasIGIsaac Garcia-Murillas
- Nick TurnerNTNick Turner
- Susan LalondrelleSLSusan Lalondrelle
- Shreerang A. BhideSBShreerang A. Bhide
Open Access
Abstract
Background: High-risk HPV infection is responsible for >99% of cervix cancers (CC). In persistent infections that lead to cancer, the tumour breaches the basement membrane, releasing HPV-DNA into the bloodstream (cHPV-DNA). A next-generation sequencing assay (NGS) for detection of plasma HPV circulating DNA (cHPV-DNA) has demonstrated high sensitivity and specificity in patients with locally advanced cervix cancers. We hypothesised that cHPV-DNA is detectable in early invasive cervical cancers but not in pre-invasive lesions (CIN). Methods: Blood samples were collected from patients with CIN (n = 52) and FIGO stage 1A-1B CC (n = 12) prior to treatment and at follow-up. DNA extraction from plasma, followed by NGS, was used for the detection of cHPV-DNA. Results: None of the patients with pre-invasive lesions were positive for CHPV-DNA. In invasive tumours, plasma from one patient (10%) reached the threshold of positivity for cHPV-DNA in plasma. Conclusion: Low detection of cHPV-DNA in early CC may be explained by small tumour size, poorer access to lymphatics and circulation, and therefore little shedding of cHPV-DNA in plasma at detectable levels. The detection rate of cHPV-DNA in patients with early invasive cervix cancer using even the most sensitive of currently available technologies lacks adequate sensitivity for clinical utility.Keywords
Funding Information
- The Royal Marsden NHS Foundation Trust (ICiC5, A67)
- The Institute of Cancer Research (ICiC5, A67)
- joint Royal Marsden and Imperial confidence (ICiC5, A67)
- National Institute for Health and Care Research (ICiC5, A67)
This publication has 26 references indexed in Scilit:
- Circulating human papillomavirus DNA detected using droplet digital PCR in the serum of patients diagnosed with early stage human papillomavirus‐associated invasive carcinomaThe Journal of Pathology: Clinical Research, 2016
- Mutation tracking in circulating tumor DNA predicts relapse in early breast cancerScience Translational Medicine, 2015
- Human Papillomavirus Mutational Insertion: Specific Marker of Circulating Tumor DNA in Cervical Cancer PatientsPLOS ONE, 2012
- Cell-free and cell-bound circulating nucleic acid complexes: mechanisms of generation, concentration and contentExpert Opinion on Biological Therapy, 2012
- Elevation of HPV-18 and HPV-16 DNA in the Plasma of Patients with Advanced Cervical Cancer2011
- BEDTools: a flexible suite of utilities for comparing genomic featuresBioinformatics, 2010
- The Sequence Alignment/Map format and SAMtoolsBioinformatics, 2009
- The Epidemiology of Human Papillomavirus Infection and Cervical CancerDisease Markers, 2007
- HPV DNA in plasma of patients with cervical carcinomaJournal of Clinical Virology, 2004
- Clinical significance of serum human papillomavirus DNA in cervical carcinomaObstetrics & Gynecology, 2003